Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colorectal resection cases in Ohio: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 10 | 2,579 | 47% |
| 2020 | 5 | 2,209 | 50% |
| 2021 | 7 |
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Ohio; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 75 | 6,844−3.3%/yr | −3.3%/yr | 6.61.1× | 5% | 7,430 in 2030+1.4%/yr |
| Cholecystectomy & appendectomy |
Colorectal resection in every state, and its device makers · Every procedure market in Ohio · Every state · Compare with Illinois
| 2024 |
| 1,916 |
| 60% |
| 2025 est. | ≈ 1,970 | – |
| 2026 est. | ≈ 2,020 | – |
| 2,242 |
| 53% |
| 2022 | 6 | 2,039 | 56% |
| 2023 | 8 | 2,076 | 58% |
| 2024 | 8 | 1,916 | 60% |
| 2025 from claims | – | 1,966 1,805–2,081 | 61% |
| 2026 forecast | – | 2,020 1,777–2,331 | 61% |
| 2027 forecast | – | 2,026 1,732–2,414 | 61% |
| 2028 forecast | – | 2,032 1,696–2,488 | 61% |
| 2029 forecast | – | 2,038 1,665–2,556 | 62% |
| 2030 forecast | – | 2,044 1,637–2,619 | 62% |
In 2025, 98% inpatient hospital, 2% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| −11%/yr |
| 1.6 |
| 0% |
| 1,170 in 2030−1.7%/yr |
| Missouri | 6 | 1,232−5.9%/yr | −5.9%/yr | 2.0 | 0% | 1,250 in 2030+0.2%/yr |
| Indiana | 3 | 1,174−6.4%/yr | −6.4%/yr | 1.7 | 0% | 1,190 in 2030+0.2%/yr |
| Wisconsin | 1 | 955−4%/yr | −4%/yr | 1.7 | 0% | 1,070 in 2030+1.9%/yr |
| Minnesota | 1 | 849−4.5%/yr | −4.5%/yr | 1.9 | 0% | 1,120 in 2030+4.8%/yr |
| Kansas | 4 | 782−3.5%/yr | −3.5%/yr | 2.0 | 0% | 730 in 2030−1.1%/yr |
| Iowa | 3 | 615−5.1%/yr | −5.1%/yr | 1.4 | 0% | 570 in 2030−1.3%/yr |
| Nebraska | 2 | 506−3.8%/yr | −3.8%/yr | 2.0 | 0% | 480 in 2030−0.8%/yr |
| South Dakota | 1 | 271−6.1%/yr | −6.1%/yr | 2.1 | 0% | 320 in 2030+2.7%/yr |
| North Dakota | 0 | 196−4.4%/yr | −4.4%/yr | 2.0 | 0% | 230 in 2030+2.4%/yr |
| 70 |
| 4,777−4.3%/yr |
| −4.3%/yr |
| 4.51.0× |
| 1% |
| 5,070 in 2030+1%/yr |
| Antireflux & hiatal hernia surgery | 13 | 867−1.9%/yr | −1.9%/yr | 0.81.0× | 0% | 880 in 2030+0.2%/yr |
| Breast reconstruction | 1 | 469−2.5%/yr | −2.5%/yr | 0.41.0× | 0% | 380 in 2030−3.5%/yr |
| Bariatric surgery | 0 | 199−17%/yr | −17%/yr | 0.20.9× | 0% | 130 in 2030−6.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Intuitive Surgical leads with 63% of company spending on these surgeons in 2025, −3 pts on 2024.
In 2025, 3 companies reported engagement with Ohio’s surgeons worth $414K in consulting, speaking, meals and travel tied to these products, about $52K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.